Most researchers searching for CJC-1295 in Olla rapidly learn that local retail options are nearly impossible to find. What this means for Olla researchers is that your location matters far less than your ability to evaluate vendor quality — and those verification methods are within reach of all serious researchers. The key verification criteria for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. This guide walks Olla researchers through that evaluation process and explains what quality documentation for CJC-1295 should look like.
What Studies Say About CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Olla comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
The most reliable path to quality CJC-1295 is starting with community forums — peptide forums maintain informal vendor reputation databases that are more trustworthy than marketing materials. Mass spectrometry in the COA confirms that the main HPLC peak is actually CJC-1295 and not a different peptide of similar polarity — HPLC purity alone provides no identity confirmation. The combination of community reputation data and your own COA analysis is the most reliable sourcing approach — community feedback surfaces patterns individual COA review misses, and vice versa. For Olla researchers making a first CJC-1295 purchase: work through this evaluation framework first, start with a modest quantity, and check that batch numbers on your vial match the COA before use.
Order CJC-1295 — ships to Olla
COA-verified · International tracking · Research grade
CJC-1295 operates outside approved pharmaceutical regulation — researchers should understand that the risk characterisation for this compound is based on academic studies rather than pharmaceutical approval data. Storage requirements for CJC-1295: lyophilised powder at freezer temperature, reconstituted solution refrigerated at 2-8°C and finished within 30 days of reconstitution; reconstitute only with sterile bacteriostatic water. Quality CJC-1295 sourcing is not separable from research safety — bacterial endotoxin contamination, mislabeling, and degradation products are all safety issues that verified-quality sourcing directly prevents. The research literature on CJC-1295 should be studied thoroughly before planning any study — study designs, dosing ranges, and outcome measures vary significantly and conclusions do not uniformly extrapolate.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
